Publication details
Nové možnosti léčby srdečního selhání a hypertenze
| Title in English | New possibilities for heart failure and hypertension therapy |
|---|---|
| Authors | |
| Year of publication | 2013 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | hypertension; heart failure; LCZ 696; serelaxin |
| Description | The therapy for reducing heart failure and hypertension has been extended by new medicines that mainly affect vasodilation. The first medicine is a dual inhibition of angiotensine II receptors (ARB) and neprilysin (NEP). It is currently, both experimentally and clinically, being tested for use in hypertension and heart failure therapy. It is based on the positive clinical effects of ARB and inhibition of vasoactive natriuretic peptides breakdown. The first large clinical trial of hypertension therapy showed sufficient hypotensive effect of LCZ 696 in heart failure with preserved ejection fraction. LCZ 696 significantly reduced the concentration of NT- proBNP. Another medicine is serelaxin (RLX030), the first recombinant form of the human hormone relaxin-2. During pregnancy, relaxin modulates cardiovascular response with vasodilation and improves renal function. Its effect has been studied in acute heart failure, Pre-RELAX- AHF and RELAX- AHF trials, which demonstrated favourable hemodynamic effects and also reduction in the 180- day mortality. |